| Xuong Wilkinson, MD | |
|
483 West Seed Farm Road, Sacaton, AZ 85147 | |
| (602) 528-1200 | |
| (602) 528-1255 |
| Full Name | Xuong Wilkinson |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 483 West Seed Farm Road, Sacaton, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538167051 | NPI | - | NPPES |
| 031815 | Other | AZ | MEDICARE |
| 031814 | Other | AZ | MEDICARE |
| 031820 | Other | AZ | MEDICARE |
| 031813 | Other | AZ | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 34158 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Huhu Kam Memorial Hospital | Sacaton, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gila River Health Care Corporation | 0648174185 | 173 |
News Archive
Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
"A global study mapping human diseases that come from animals like tuberculosis, AIDS, bird flu or Rift Valley fever has found that just 13 such diseases are responsible for 2.4 billion cases of human illness and 2.2 million deaths a year," Reuters reports.
A natural substance known to activate pain in the central nervous system has been found to have the opposite effect in other parts of the body, potentially paving the way to new methods of pain control.
FzioMed, a medical device company that recently celebrated the 17th anniversary of its founding, has received approval from the Commissioner of the U.S. Food and Drug Administration of its Petition for an independent review of its premarket approval application for Oxiplex Gel.
› Verified 1 days ago
| Entity Name | Gila River Health Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376538231 PECOS PAC ID: 0648174185 Enrollment ID: O20031125000648 |
News Archive
Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
"A global study mapping human diseases that come from animals like tuberculosis, AIDS, bird flu or Rift Valley fever has found that just 13 such diseases are responsible for 2.4 billion cases of human illness and 2.2 million deaths a year," Reuters reports.
A natural substance known to activate pain in the central nervous system has been found to have the opposite effect in other parts of the body, potentially paving the way to new methods of pain control.
FzioMed, a medical device company that recently celebrated the 17th anniversary of its founding, has received approval from the Commissioner of the U.S. Food and Drug Administration of its Petition for an independent review of its premarket approval application for Oxiplex Gel.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Xuong Wilkinson, MD Po Box 38, Sacaton, AZ 85147-0038 Ph: (602) 528-1200 | Xuong Wilkinson, MD 483 West Seed Farm Road, Sacaton, AZ 85147 Ph: (602) 528-1200 |
News Archive
Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
"A global study mapping human diseases that come from animals like tuberculosis, AIDS, bird flu or Rift Valley fever has found that just 13 such diseases are responsible for 2.4 billion cases of human illness and 2.2 million deaths a year," Reuters reports.
A natural substance known to activate pain in the central nervous system has been found to have the opposite effect in other parts of the body, potentially paving the way to new methods of pain control.
FzioMed, a medical device company that recently celebrated the 17th anniversary of its founding, has received approval from the Commissioner of the U.S. Food and Drug Administration of its Petition for an independent review of its premarket approval application for Oxiplex Gel.
› Verified 1 days ago
Dr. Monica A Lumpkin, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 483 W. Seed Farm Rd., Sacaton, AZ 85147 Phone: 602-528-1200 Fax: 602-528-1255 | |
Dr. Thomas Daniel Rowe, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 483 W Seed Farm Rd, Sacaton, AZ 85147 Phone: 602-528-1200 Fax: 602-528-1255 | |
Quynh Le, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 483 W. Seed Farm Rd., Gila River Health Care/hu Hu Kam Memorial Hospital, Sacaton, AZ 85147 Phone: 602-528-1200 Fax: 602-528-1255 | |
Dr. Evelyn Q Aguila, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 483 W Seed Farm Rd, Sacaton, AZ 85248 Phone: 602-528-1340 Fax: 602-528-1296 | |
Sisy Thomas, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: Hu Hu Kam Memorial Hospital, 483 W. Seed Farm Rd, Sacaton, AZ 85147 Phone: 602-528-1458 Fax: 602-271-7870 | |
Dr. Roger F Villalba, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 483 W. Seed Farm Rd., Sacaton, AZ 85147 Phone: 602-528-1200 |